Compare

IDEXX Laboratories vs Illumina

MonkScore ranges and fundamentals, side by side

Key facts

IDEXX Laboratories and Illumina: key facts

  • In fiscal 2025, IDEXX Laboratories, Inc. reported revenue of $4.3B and net income of $1.1B.
  • In fiscal 2025, Illumina, Inc. reported revenue of $4.3B and net income of $850.0M.
  • IDEXX Laboratories, Inc.'s revenue grew 7.6% a year from fiscal 2021 to fiscal 2025.
  • Illumina, Inc.'s revenue fell 1.1% a year from fiscal 2021 to fiscal 2025.
  • IDEXX Laboratories, Inc.'s free cash flow was positive in 5 of the 5 fiscal years from 2021 to 2025.
  • Illumina, Inc.'s free cash flow was positive in 5 of the 5 fiscal years from 2021 to 2025.
  • In the twelve months to 30 September 2026, IDEXX Laboratories, Inc. reported revenue of $4.7B and net income of $1.2B.
  • In the twelve months to 27 September 2026, Illumina, Inc. reported revenue of $4.5B and net income of $895.0M.

Side by side

IDEXX Laboratories and Illumina, side by side

Each figure is in the company's reporting currency, with its fiscal year or the date of its last report.

FigureIDEXX Laboratories, Inc.NASDAQ:IDXXIllumina, Inc.NASDAQ:ILMN
MonkScore
MonkScore range90–100as of November 202690–100as of November 2026
Sector rank1 of 630 in Healthcare27 of 630 in Healthcare
How this score is madeDisclaimer
Profile
SectorHealthcareHealthcare
IndustryMedical - Diagnostics & ResearchMedical - Diagnostics & Research
Latest fiscal year
Revenue$4.3BFY 2025$4.3BFY 2025
Net income$1.1BFY 2025$850.0MFY 2025
Free cash flow$1.1BFY 2025$931.0MFY 2025
Operating cash flow$1.2BFY 2025$1.1BFY 2025
Total debt$1.1BFY 2025$2.6BFY 2025
Cash$180.1MFY 2025$1.4BFY 2025
Last 12 months
Revenue$4.7Bto 30 September 2026$4.5Bto 27 September 2026
Net income$1.2Bto 30 September 2026$895.0Mto 27 September 2026
Free cash flow$1.3Bto 30 September 2026$1.1Bto 27 September 2026
Operating cash flow$1.4Bto 30 September 2026$1.2Bto 27 September 2026
Total debt$973.0Mto 30 September 2026$2.3Bto 27 September 2026
Cash$197.5Mto 30 September 2026$1.3Bto 27 September 2026

MonkStreet provides research, not investment advice.